Compare FIRY & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FIRY | CGEN |
|---|---|---|
| Founded | 2012 | 1993 |
| Country | United States | Israel |
| Employees | N/A | 75 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 177.9M | 201.8M |
| IPO Year | 2020 | 2001 |
| Metric | FIRY | CGEN |
|---|---|---|
| Price | $12.01 | $2.12 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 145.5K | ★ 169.5K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $104,496,000.00 | N/A |
| Revenue This Year | $22.11 | N/A |
| Revenue Next Year | $7.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 12.52 | N/A |
| 52 Week Low | $7.92 | $1.43 |
| 52 Week High | $14.12 | $3.24 |
| Indicator | FIRY | CGEN |
|---|---|---|
| Relative Strength Index (RSI) | 57.19 | 30.07 |
| Support Level | $9.31 | $1.98 |
| Resistance Level | $14.02 | $2.35 |
| Average True Range (ATR) | 0.84 | 0.08 |
| MACD | -0.09 | -0.03 |
| Stochastic Oscillator | 40.19 | 17.58 |
Firy Inc, formerly Skillz Inc is a two-sided mobile gaming platform that connects developers with competitive players. Its reportable segments are: the Skillz segment and the RZR segment. Skillz segment's highlights include Monetize Through Competitions, Player Matching, Cross-Platform Support, Comprehensive Analytics, and Focus on Game Development. Aarki is a performance marketing platform that enables advertisers to acquire, retain, and monetize users across mobile, connected television (CTV), and other digital channels. Some of the games available on its platform are Dominoes Gold, Blackout Bingo, 21 Blitz, and Solitaire Cube, among others. It generates the majority of its revenue from the Skillz segment. Geographically, the company derives its key revenue from the United States.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing Unigen, its AI/ML-powered computational discovery capabilities, to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs: COM701, COM902, rilvegostomig, and GS-0321 (previously COM503), targeting immune checkpoints the company discovered computationally. The company's revenues are generated mainly from collaborative and license agreements. Geographically, it generates maximum revenue from the United Kingdom, and the rest from the United States.